Title:
IMPROVEMENT OF TUMOR IMMUNOGENICITY BY MEANS OF SPLICING-CONTROLLING COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/033189
Kind Code:
A1
Abstract:
Provided is a pharmaceutical composition which can improve the immunogenicity of a tumor. The present disclosure relates to a pharmaceutical composition containing, as an active ingredient, a splicing-controlling compound that regulates the activity of serine/arginine-rich splicing factors (SRSFs).
More Like This:
Inventors:
HAGIWARA MASATOSHI
AJIRO MASAHIKO
MATSUSHIMA SHINGO
AJIRO MASAHIKO
MATSUSHIMA SHINGO
Application Number:
PCT/JP2022/033464
Publication Date:
March 09, 2023
Filing Date:
September 06, 2022
Export Citation:
Assignee:
UNIV KYOTO (JP)
International Classes:
A61K39/00; A61K31/427; A61K31/52; A61K38/03; A61K45/00; A61K45/06; A61P35/00; A61P37/04; C07K7/06; C12N15/11
Domestic Patent References:
| WO2018151326A1 | 2018-08-23 |
Other References:
LU SYDNEY X.; DE NEEF EMMA; THOMAS JAMES D.; SABIO ERICH; ROUSSEAU BENOIT; GIGOUX MATHIEU; KNORR DAVID A.; GREENBAUM BENJAMIN; ELH: "Pharmacologic modulation of RNA splicing enhances anti-tumor immunity", CELL, ELSEVIER, AMSTERDAM NL, vol. 184, no. 15, 24 June 2021 (2021-06-24), Amsterdam NL , pages 4032, XP086701320, ISSN: 0092-8674, DOI: 10.1016/j.cell.2021.05.038
SHIBATA SAIKO; AJIRO MASAHIKO; HAGIWARA MASATOSHI: "Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 12, 8 September 2020 (2020-09-08), AMSTERDAM, NL , pages 1472, XP086414564, ISSN: 2451-9456, DOI: 10.1016/j.chembiol.2020.08.013
DATABASE PROTEIN ANONYMOUS : "major facilitator superfamily domain-containing protein 1 [Heterostelium album PN500] ", XP093042942, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "hypothetical protein VMCG_09954 [Valsa malicola]", XP093042938, retrieved from NCBI
CANCER DISCOV, 2 April 2021 (2021-04-02)
CELL, vol. 184, no. 15, 22 July 2021 (2021-07-22), pages 4032 - 4047
NAT COMMUN, vol. 2, 2011, pages 308
PROC NATL ACAD SCI USA., vol. 112, no. 9, 3 March 2015 (2015-03-03), pages 2764 - 9
SCI REP, vol. 7, 30 May 2017 (2017-05-30), pages 46126
J CLIN INVEST, vol. 129, no. 2, 1 February 2019 (2019-02-01), pages 583 - 597
CELL CHEM BIOL, vol. 27, no. 12, 17 December 2020 (2020-12-17), pages 1472 - 1482
NAT COMMUN, vol. 12, no. 1, 23 July 2021 (2021-07-23), pages 4507
CELL CHEM BIOL., vol. 27, 2020, pages 1472 - 1482
SHIBATA SAIKO; AJIRO MASAHIKO; HAGIWARA MASATOSHI: "Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion", CELL CHEMICAL BIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 12, 8 September 2020 (2020-09-08), AMSTERDAM, NL , pages 1472, XP086414564, ISSN: 2451-9456, DOI: 10.1016/j.chembiol.2020.08.013
DATABASE PROTEIN ANONYMOUS : "major facilitator superfamily domain-containing protein 1 [Heterostelium album PN500] ", XP093042942, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "hypothetical protein VMCG_09954 [Valsa malicola]", XP093042938, retrieved from NCBI
CANCER DISCOV, 2 April 2021 (2021-04-02)
CELL, vol. 184, no. 15, 22 July 2021 (2021-07-22), pages 4032 - 4047
NAT COMMUN, vol. 2, 2011, pages 308
PROC NATL ACAD SCI USA., vol. 112, no. 9, 3 March 2015 (2015-03-03), pages 2764 - 9
SCI REP, vol. 7, 30 May 2017 (2017-05-30), pages 46126
J CLIN INVEST, vol. 129, no. 2, 1 February 2019 (2019-02-01), pages 583 - 597
CELL CHEM BIOL, vol. 27, no. 12, 17 December 2020 (2020-12-17), pages 1472 - 1482
NAT COMMUN, vol. 12, no. 1, 23 July 2021 (2021-07-23), pages 4507
CELL CHEM BIOL., vol. 27, 2020, pages 1472 - 1482
Attorney, Agent or Firm:
IKEUCHI & PARTNERS (JP)
Download PDF: